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Background: Peritoneal carcinomatosis develops in 15 % of patients with primary colorectal cancer (CRC) and in
25 % of those with recurrence. Liver metastases are also frequent and appear at some time in 35–55 % of patients
with CRC. When both conditions are present and treated palliatively, the expected median survival is 5–6 months.
Recent publications suggest survival is improved when R0 resection of both peritoneal and liver diseases is
achieved.
Case presentation: A 36-year-old woman with synchronous peritoneal and liver metastases of colorectal origin
was treated with a stepwise approach consisting of initial cytoreductive surgery, minor liver resection,
intraperitoneal intraoperative hyperthermic chemotherapy, adjuvant chemotherapy, right portal embolization, and
finally, right hepatectomy achieving an R0 resection. The patient is alive and free of disease after 30 months of
follow-up.
Discussion: Patients with peritoneal carcinomatosis and liver metastases from CRC must be carefully evaluated by
multidisciplinary oncological teams in order to offer the possibility of surgery to obtain an R0 resection in selected
patients (especially if the peritoneal cancer index is <19 and there is resectable or potentially resectable metastatic
liver disease).
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Peritoneal carcinomatosis develops in 15 % of patients
with primary colorectal cancer (CRC) and in 25 % of those
with a recurrence. Liver metastases are also frequent and
appear at some time in 35–55 % of patients with CRC. In
a retrospective analysis of 5638 patients diagnosed with
metastatic CRC in 1995–2010, Thomassen et al. found
8 % of cases with simultaneous liver and peritoneal dis-
eases treated palliatively, with a median overall survival
(OS) of 5 months. This poor OS has remained unchanged
over the years (12 months when the best available* Correspondence: cprptot@gmail.com
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creativecommons.org/publicdomain/zero/1.0/chemotherapy was applied vs. 2.6 months when no treat-
ment was given) [1].
Peritoneal carcinomatosis has been classically consid-
ered as a pre-terminal condition with a poor prognosis
(median OS of 6 months with the best palliative treat-
ment). Based on Sugarbaker’s initial studies, a growing
number of publications have appeared in the last 15 years
reporting median OS of 24 months and overall long-
term survival rates of 22–49 % for selected patients
treated using an aggressive surgical approach, consisting
of maximum cytoreduction plus hyperthermic intraperi-
toneal chemotherapy (HIPEC) [2, 3]. The American So-
ciety of Peritoneal Surface Malignancies (ASPSM) has
recently established 30 months as the expected median
survival for patients with peritoneal carcinomatosis ofcess article distributed under the terms of the Creative Commons Attribution
by/4.0), which permits unrestricted use, distribution, and reproduction in any
ly credited. The Creative Commons Public Domain Dedication waiver (http://
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multidisciplinary approach [4] .
The only treatment associated with a long-term OS and
eventual cure for patients with liver metastases of colorec-
tal origin is resection with free margins, leaving sufficient
remaining hepatic parenchyma (at least two hepatic seg-
ments with adequate arterial and portal supply and venous
and biliary drainage). This can only be achieved in
10–15 % of cases, though it has an overall 5-year survival
rate of 44–47 % and a disease-free survival rate of 30 %
[5, 6]. The use of strategies that increase the resectability
of liver metastases (mainly induction chemotherapy, por-
tal embolization, and the two-stage hepatectomy ap-
proach) has allowed resection in an additional 10–15 % of
patients who were previously considered to have non-
resectable disease, obtaining OS rates comparable to those
of patients on first-line treatment [7].
Conceptually, the presence of metastatic liver disease
is considered a contraindication for the cytoreduction +
HIPEC approach in patients with peritoneal carcinoma-
tosis. Similarly, the presence of peritoneal disease pre-
cludes a curative resection of liver metastasis. However,
following reports of curative surgical attempts to treat
the two metastatic sites separately, the first retrospective
studies have been published showing that combined sur-
gery of peritoneal and liver diseases is feasible and has
an impact on survival in selected patients. Liver resec-
tions have so far always been performed in a single pro-
cedure (before, simultaneously, or after cytoreduction +
HIPEC), and though most were limited resections, seg-
mentectomies, major hepatectomies, and local ablative
therapies have also been performed.
We report the case of a patient who had simultaneous
peritoneal and liver metastatic diseases and was treated
at our hospital using a stepwise multidisciplinary onco-
surgical approach. This approach involved a novel se-
quence of actions, unreported until now for these cases,
by combining liver resection (minor and major), cytore-
duction + HIPEC, systemic chemotherapy, and portal
embolization until an R0 status was achieved.
Case presentation
An otherwise healthy 36 year-old woman was treated else-
where for a perforated peri-sigmoid abscess and purulent
peritonitis with sigmoidectomy and a primary mechanical
colorectal anastomosis (time 0). Postoperative recovery
was good, and the histopathology report described a well-
differentiated adenocarcinoma (T4aNxMx, due to the ab-
sence of nodes in the surgical specimen). She was referred
to the medical oncologist for palliative treatment. CEA
level was 23 μU/l. A positron emission tomography-
computed tomography (PET-CT) showed uptake in mul-
tiple nodes of greater than 1 cm in the pelvis (Fig. 1a–c)
and two hepatic lesions suspicious for metastases (onemore peripheral in segment II of 1.8 cm and the other in
segment V of 2.5 cm just at the right portal bifurcation)
(Fig. 2a–b). There was no extra-abdominal uptake. She
came to our center to request an assessment. Her per-
formance status on the Karnofsky scale was 100 % (no
signs or symptoms of disease). Complete tumor resection
was proposed and completed. This consisted of the
following:
1. First surgery (week +7): a full midline laparotomy
revealed a peritoneal carcinomatosis index (PCI) of 8
in the Sugarbaker classification and disease located
predominantly in the pelvis [8]. As intraoperative
liver ultrasound showed that the segment V lesion
would require a right hepatectomy to achieve a
complete R0 resection we just performed a limited
segment II resection to treat the smallest liver lesion.
A complete CC-0 cytoreduction (complete centri-
petal peritonectomy of the pelvis with a posterior
pelvic-compartment exenteration and an oncological
left hemicolectomy with colorectal reconstruction)
was performed with intraoperative blood loss of
210 cc. This was followed by HIPEC with intraperi-
toneal oxaliplatin adjusted for the body surface at
43 °C for 30 min. The patient was discharged with-
out complications on the ninth postoperative day.
The biopsy confirmed the presence of peritoneal and
liver metastasis with a well-differentiated non-
mucinous adenocarcinoma. A K-RAS oncogene
study was negative for mutation.
2. Six postoperative cycles with capecitabine,
oxaliplatin, and cetuximab were given with good
tolerance (weeks +12 to +26). A control PET-CT
showed a complete radiological response with remis-
sion of the hepatic lesion of segment V.
3. Percutaneous right portal vein embolization (week
+27). The growth of the left liver lobe after 4 weeks
was 35 %, accounting for 43 % of the total hepatic
volume.
4. Second surgery (week +31): an anatomical right
hepatectomy was performed with a Pringle
maneuver, i.e., clamping of the complete liver inflow
at the hepatic hilum for 20 min, requiring
transfusion of one unit of packed red cells (Fig. 3).
Recovery was good, and the patient was discharged
on postoperative day +8 with no complications. The
histological report of the nodule was fibrosis without
residual tumor cells (complete microscopic
remission).
Postsurgical consolidation systemic chemotherapy was
not considered necessary by the medical oncologist, and
the patient is currently disease free after 30 months of
follow-up.
Fig. 1 a-c PET-CT pathologic uptake in the pelvis, revealing peritoneal carcinomatosis of colorectal cancer
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No clear therapeutic action can currently be defined for
patients with coexisting peritoneal carcinomatosis and
liver metastasis of colorectal origin when these are the
only sites of disseminated disease. The systematic review
by De Cuba et al. only found a trend (with no statistical
significance) towards increased OS of patients who just
had peritoneal disease compared to those who had me-
tastasis in both sites when an R0 resection was per-
formed. They also concluded that there was no solid
evidence in the literature to justify the exclusion of se-
lected patients for resective liver surgery and cytoreduc-
tion + HIPEC [9]. The key point is patient selection in
order to balance the extent of the disease with the com-
plexity of the surgery required.
Studies on liver resection combined with cytoreduc-
tion + HIPEC for the treatment of metastatic colorectal
cancer are retrospective and heterogeneous and present
contradictory results (wide variation in the number of
cases, centers included, type of liver resections consid-
ered, with or without ablative therapies, timing of cytor-
eduction + HIPEC, and techniques used to administer
intraperitoneal chemotherapy). Kianmanesh et al., Chua
et al., and Varban et al. reported historical series of pa-
tients with peritoneal carcinomatosis subjected to cytor-
eduction + HIPEC and included a subgroup in whichFig. 2 a-b PET-CT images locating the two liver metastases, the first in seg
segment IIliver resection for metastases was also performed, find-
ing no differences in OS between the groups [10–12].
Similarly, Elias et al. in a French multicenter study in-
cluding 523 patients with peritoneal carcinomatosis of
colorectal origin (95 % of cases having optimal cytore-
duction, CC-0 or CC-1) did not find that the presence of
liver metastasis (n = 77) and its simultaneous resection
had a negative impact on OS (5-year OS of 21 vs. 27 %)
[13]. However, Glehen et al., in a European multicenter
review of 506 cases of peritoneal carcinomatosis of colo-
rectal origin, identified liver metastases as a negative
prognostic factor of survival (16.8 vs. 20.4 months), but
optimal cytoreduction was only achieved in 74.5 % of
the patients [14]. In all these studies, the administration
of systemic adjuvant chemotherapy after surgery proved
to be a favorable prognostic factor for survival. Maggiori
et al. published a retrospective cohort study comparing a
historic series from the Gustave-Roussy Institute of 37
cases treated for simultaneous peritoneal and liver me-
tastases of colorectal origin with a group of 61 controls
who had been treated for peritoneal disease as the only
form of metastasis during the same period (Table 1). A
peritoneal cancer index (PCI) >12 and simultaneous liver
and peritoneal surgery were negative predictive factors
for survival. Thus, they established the first prognostic
stratification based on a logistic regression model forment IV-B next to the right portal bifurcation and the other in
Fig. 3 CT image showing the volume of the left liver lobe
immediately after the right hepatectomy and free of disease
(hypertrophy is evident)
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metastases, median survival of 76 months; PCI <12 and
presence of one or two liver metastases, 40 months; and
finally, PCI >12 or more than two liver tumors, 27
months [15]. The most recent reviews suggest no benefit
in OS by performing radical surgery accompanied by
HIPEC in patients with a PCI >19. However, as a few se-
lected patients with a PCI = 12–19 or >2 liver metastases
can benefit from a combined radical approach patients
should be individualized. In our patient, who only had
two identified liver lesions and a preoperative PCI <12
estimated from the CT and PET-CT images, we consid-
ered a strategy to achieve an R0 status as the best op-
tion. Our limiting factor was the complex site of the
right liver lesion (requiring a right hepatectomy), which
led us to design a multidisciplinary, step-by-stepTable 1 Major published series of patients undergoing surgery for c
colorectal cancer
Author Year n (peritoneal + liver/total) OS (peritoneal + live
Kianmanesh
et al.
2007 37.2 % (16/43) 36 vs. 35.3 months
Chua et al. 2009 29.1 % (16/55) 65 vs. 68 %, 2 years
Varban et al. 2009 9.9 % (14/142) 23 vs. 15.8 months
43.3 vs. 36.8 %, 2 ye
Elias et al. 2009 14.72 % (77/523) 21 vs. 27 %, 5 years
Glehen et al. 2004 12.15 % (61/502) 16.8 vs. 20.4 month
Maggiori et al. 2013 37 vs. 60 40 vs. 66 %, 3 years
32 vs. 49 monthsapproach using all the medical, technical and radio-
logical resources, and information from the liver and
peritoneal biopsies.
The management of the liver metastases in series of
Table 1 does not correspond with current modern cri-
teria for optimizing OS after liver surgery because there
are R1 or R2 resections, ablative treatments mixed with
surgery, and different types and extension of liver resec-
tions. Radical R0 liver resection is the most important
known prognostic factor in surgery of liver metastasis
and has a 5-year OS of 32 % [16, 17]. Patients subjected
to ablative therapies, either as single therapy or comple-
mentary to hepatectomy, cannot be considered in the
same group as those who just undergo resection. Series
with long follow-up periods have shown that they are
not comparable treatments because local recurrences are
greater and nearly universal (1.7–66.7 % for ablative vs.
1.2–10.4 % for resection) [18]. On the other hand, the
extension of the hepatectomy (major or major extended
vs. minor), the need for perioperative transfusion (which
is also dose-dependent), and postoperative complications
(particularly infectious morbidity and postoperative liver
failure) are considered negative prognostic factors for
survival by increasing the risk of recurrence, which oc-
curs exclusively in the liver in almost half the cases
(43.2 %) [6, 19–21].
The initial studies by Paul Brousse demonstrated that
up to 12.5 % of patients with liver metastases initially
considered as non-resectable were able to be rescued
secondarily for complete radical surgery when they were
subjected to systemic chemotherapy with a chronomo-
dulated infusion (5-FU + Leucovorin + Oxaliplatin or Iri-
notecan), with 5- and 10-year disease-free survival rates
of 22 and 17 %, respectively [22]. This “neoadjuvant”
chemotherapy has also been applied, in historic series, tooexisting peritoneal carcinomatosis and liver metastases from
r/only peritoneal) Observations
No differences between groups
Only 70 % of patients having CC-0 or CC-1 surgery
No differences between groups
Group of combined liver and peritoneal, lower
PCI (8 vs. 12)
No differences between groups
ars Median number and size of liver metastasis: 1 (1–7)
and 3 cm (0.4–12)
Multicentric study
No differences between groups
s Liver metastasis as negative predictive factor
for OS (p = 0.008)
Median OS 40 months for PCI <12 and 1 or 2 liver
metastases
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minimize the extension of the hepatectomy required to
obtain curative resections (thus decreasing morbidity
and mortality), eliminate potential extra-hepatic micro-
metastasis, evaluate chemosensitivity (identifying and
discarding patients for surgery who progress during sys-
temic chemotherapy), and finally to evaluate the histo-
logical regression response, which is known to be a
positive prognostic factor of survival. The analysis of
long-term OS in EORTC 40983, a prospective random-
ized multicenter trial that compared patients with four
or less resectable liver metastases subjected to systemic
chemotherapy before and after surgery or only to sur-
gery, found no difference (51.2 vs. 47.8 % at 5 years),
despite the fact that the initial results indicated im-
proved disease-free survival for the first group (42.4 vs.
33.2 %) [23]. Thus, although it has not been possible to
demonstrate the benefits in terms of survival of neoadju-
vant systemic chemotherapy for resectable liver disease
with a high level in evidence-based medicine, its use
seems appropriate because it enables selection of patient
subgroups with a better prognosis, and for some patients
in progression, it avoids surgery (which will not contrib-
ute in the natural course of the disease). In our case, we
recommended chemotherapy after the first peritoneal
surgery as an adjuvant option and to evaluate the re-
sponse of the remnant liver during this period, in order
to obtain biologic information about the disease.
Patients with multiple liver metastases treated with sys-
temic chemotherapy usually require more than one liver
surgery procedure, as do patients with liver lesions due to
different forms of toxicity (non-alcoholic steatosis and si-
nusoidal obstruction syndrome, mainly associated with
oxaliplatin and irinotecan). Portal embolization and two-
stage hepatectomy have been the strategies that have
helped liver surgeons to achieve more R0 resections in the
most technically complex and extreme cases, those in
which it is estimated that there is a residual preoperative
volume of <25 % of healthy liver, or <30–40 % with base-
line liver steatosis or damage by chemotherapy. Portal
embolization enables safer liver resection and, further-
more, increases the number of patients susceptible to
major hepatectomy by 20 %, with a 5-year survival rate of
around 40 % (similar to that obtained without portal
embolization) [24]. The two-stage approach allows an R0
resection in a multifocal metastatic liver in two operations
that was previously untreatable in one-time surgery. The
first time is usually for minor liver surgery (limited resec-
tions or of less than three segments), and the second time
is reserved for major surgery, with portal embolization
and systemic chemotherapy support usually given in the
interval between the procedures. A recently published sys-
tematic review reported a median survival of 37 months,
with a disease-free survival of 20 % at 3 years for patientscompleting the two-stage liver approach [25]. In our case,
the accumulated dose of chemotherapy and the need for
major liver resection warranted optimizing the liver sur-
gery by combining these two strategies.
Conclusions
1. To date, no randomized level 1 evidence is available
(nor is it likely to be) to consider surgery as the
standard or recommended treatment for patients
with coexisting peritoneal and liver metastases from
colorectal cancer. The relevant medical literature is
based on heterogeneous, retrospective, low-volume
series.
2. Optimal cytoreduction + HIPEC and liver resection
represent the best therapeutic option for selected
patients with low-volume peritoneal carcinomatosis
and liver metastases from colorectal cancer. If an R0
status can be achieved, the patient will have a clear
benefit regarding overall survival.
3. Portal embolization and two-stage hepatectomy are
strategies with proven efficacy in the treatment of
liver metastases and can be integrated into the
multidisciplinary approach for these patients in
order to increase the possibility of an R0 resection
and decrease morbidity related to the liver resection.
4. Systemic chemotherapy has a positive impact on
overall survival in patients treated surgically for
peritoneal and liver metastatic colorectal disease and
must always be used in the multi-step strategies
considered.
5. These patients must be referred to and treated at
centers with surgeons and medical teams
experienced in cytoreduction + HIPEC and surgery
for liver metastases.
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